top of page
JNJ-4804: DUET efficacy as expected, but not yet the adoption case
Efficacy was expected; adoption still depends on safety.
As highlighted in our May 2025 JNJ IBD report, the DUET-CD and DUET-UC readouts for JNJ-4804, the fixed-dose maintenance combination of Tremfya and Simponi, delivered only numerically higher rates than Tremfya alone, with materially higher remission rates than Simponi, consistent with the 12-week VEGA induction efficacy signal.
bottom of page